Open AccessTelaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
Author(s) -
Amanda Carlson,
Zachery R. Gregorich,
Rob Striker
Publication year - 2012
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cis960
Subject(s) - boceprevir , telaprevir , medicine , ribavirin , virology , rash , hepatitis c virus , virus
Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom